Principal Financial Group
CMPX icon

Principal Financial Group’s Compass Therapeutics CMPX Stock Holding History

Principal Financial Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$10K – 2262
2024
Q2 		$10K Sell
10,000
-586
-6% -$856 ﹤0.01% 2359
2024
Q1 		$21K Sell
10,586
-1,386
-12% -$2.4K ﹤0.01% 2405
2023
Q4 		$18.7K Hold
11,972
– – ﹤0.01% 2387
2023
Q3 		$23.6K Buy
+11,972
New +$29.6K ﹤0.01% 2405

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Principal Financial Group's CMPX Position: Q3 2024 in Review

Principal Financial Group sold out of Compass Therapeutics (CMPX) in Q3 2024, closing a stake of 10,000 shares — an estimated $10K sold.

Principal Financial Group first reported a position in CMPX in Q3 2023 and held it in 4 quarters. The position peaked at $23.6K in Q3 2023. 79 funds tracked by Wall St. Rank hold CMPX as of Q3 2024.

  • Principal Financial Group reported no remaining Compass Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 10,000 Compass Therapeutics shares in Q3 2024, an estimated $10K.
  • Principal Financial Group first reported a position in Compass Therapeutics in Q3 2023 and held it in 4 quarters.
  • Principal Financial Group's Compass Therapeutics position peaked at $23.6K in Q3 2023.
  • 79 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.